ORDER NOW

Single-site or operational unit license 
$2,500.00 

Global enterprise-wide license PDF:
$5000.00 

Country or Global license 
Contact David Cunningham, 
Account Manager, 
781-972-5472 
cunningham@
healthtech.com

Length 
75 pages 

Date published 
September 2006 

Additional info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

CHI Advances: Tech Update
Proteomics: Current State and Future Directions

Hermann A.M. Mucke, Ph.D.

New Page 1

CHI Advances 2006 Proteomics Survey –

  1. Please classify your organization.
  2. Please describe your organization's primary involvement in proteomics.
  3. Are you currently using proteomics to discover novel biomarkers?
  4. If you answered no to the previous question do you expect to use proteomics for discovering biomarkers in the next 3 years?
  5. Please describe the primary emphasis of your proteomics research.
  6. Which proteomics technology do you work with most frequently?
  7. Which technology do you most frequently use as a detection platform?
  8. Which technology do you expect to use most frequently as a detection platform 3 years out?
  9. What separation technique do you most frequently use?
  10. Do you run your own proteomics experiments or do you rely on a shared core facility?
  11. Do you typically run experiments on intact proteins or do you more frequently pre-digest the proteome to work with peptide fragments?
  12. Please describe the typical abundance of the proteins that you study.
  13. Do you typically pre-treat your sample to enrich it before analysis?
  14. If you use mass spectroscopy as a detection method which variety of mass spectrometer do you use?
 


About Insight Pharma Reports

How to Order

Journalist Inquiries

Corporate Librarians and Information Services Inquiries

The Insight Pharma Reports Advisory Board

Contact Insight Pharma Reports

 

"CHI's Insight
 Pharma Reports are
 a cost-effective and reliable source
 of information about the markets
 we serve. The cost
 for us to conduct
 this kind of business
 research on our
 own would be
 prohibitive. CHI's
 Insight Pharma
 Reports allow us to
 keep on top of
 developments in
 this rapidly moving
 field." 

--Donald N. Halbert, Ph.D., EVP of R&D, Iconix Biosciences

 

A division of 
Cambridge 
Healthtech Institute


CHI's Insight Pharma Reports, a division of Cambridge Healthtech Institute | 250 First Avenue | Needham, MA 02494
For more information, email Rose LaRaia at rlaraia@healthtech.com or call 781-972-5444